247 related articles for article (PubMed ID: 25374152)
41. Preclinical evaluation of immunotherapeutic regimens for fetal/neonatal alloimmune thrombocytopenia.
Zhi H; Ahlen MT; Skogen B; Newman DK; Newman PJ
Blood Adv; 2021 Sep; 5(18):3552-3562. PubMed ID: 34470046
[TBL] [Abstract][Full Text] [Related]
42. Fast and low-cost direct ELISA for high-throughput serological HPA-1a typing.
Winkelhorst D; Porcelijn L; Muizelaar E; Oldert G; Huiskes E; van der Schoot CE
Transfusion; 2019 Sep; 59(9):2989-2996. PubMed ID: 31329320
[TBL] [Abstract][Full Text] [Related]
43. Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model.
Tiller H; Killie MK; Chen P; Eksteen M; Husebekk A; Skogen B; Kjeldsen-Kragh J; Ni H
Transfusion; 2012 Jul; 52(7):1446-57. PubMed ID: 22251227
[TBL] [Abstract][Full Text] [Related]
44. A case report of prenatal diagnosis of fetal alloimmune thrombocytopenia: A CARE-compliant article.
Fu J; Yao R; Yong W
Medicine (Baltimore); 2021 Jun; 100(24):e26092. PubMed ID: 34128846
[TBL] [Abstract][Full Text] [Related]
45. Neonatal alloimmune thrombocytopenia due to anti-HPA 5a in a HPA-5a homozygous neonate.
Porta R; Serrano P; Paltrinieri A; Ristic G; Canals C; Lozano M
Transfus Apher Sci; 2020 Dec; 59(6):102880. PubMed ID: 32763115
[TBL] [Abstract][Full Text] [Related]
46. Predicting risk severity and response of fetal neonatal alloimmune thrombocytopenia.
Salomon O; Rosenberg N
Br J Haematol; 2013 Aug; 162(3):304-12. PubMed ID: 23672281
[TBL] [Abstract][Full Text] [Related]
47. Strategies to develop a prophylaxis for the prevention of HPA-1a immunization and fetal and neonatal alloimmune thrombocytopenia.
Kjær M; Geisen C; Akkök ÇA; Wikman A; Sachs U; Bussel JB; Nielsen K; Walles K; Curtis BR; Vidarsson G; Järås K; Skogen B
Transfus Apher Sci; 2020 Feb; 59(1):102712. PubMed ID: 31948915
[TBL] [Abstract][Full Text] [Related]
48. Antiendothelial αvβ3 Antibodies Are a Major Cause of Intracranial Bleeding in Fetal/Neonatal Alloimmune Thrombocytopenia.
Santoso S; Wihadmadyatami H; Bakchoul T; Werth S; Al-Fakhri N; Bein G; Kiefel V; Zhu J; Newman PJ; Bayat B; Sachs UJ
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1517-24. PubMed ID: 27283740
[TBL] [Abstract][Full Text] [Related]
49. Alloimmune thrombocytopenia of the fetus and the newborn.
Kaplan C
Blood Rev; 2002 Mar; 16(1):69-72. PubMed ID: 11914000
[TBL] [Abstract][Full Text] [Related]
50. Recent advances in non-invasive fetal HPA-1a typing.
Nogués N
Transfus Apher Sci; 2020 Feb; 59(1):102708. PubMed ID: 31953107
[TBL] [Abstract][Full Text] [Related]
51. Maternal HPA-1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review.
Kjaer M; Bertrand G; Bakchoul T; Massey E; Baker JM; Lieberman L; Tanael S; Greinacher A; Murphy MF; Arnold DM; Baidya S; Bussel J; Hume H; Kaplan C; Oepkes D; Ryan G; Savoia H; Shehata N; Kjeldsen-Kragh J;
Vox Sang; 2019 Jan; 114(1):79-94. PubMed ID: 30565711
[TBL] [Abstract][Full Text] [Related]
52. Neonatal alloimmune thrombocytopenia: antenatal management.
Silver RM; Porter TF; Branch DW; Esplin MS; Scott JR
Am J Obstet Gynecol; 2000 May; 182(5):1233-8. PubMed ID: 10819864
[TBL] [Abstract][Full Text] [Related]
53. Fetal/neonatal alloimmune thrombocytopenia.
Sachs UJ
Thromb Res; 2013 Jan; 131 Suppl 1():S42-6. PubMed ID: 23452741
[TBL] [Abstract][Full Text] [Related]
54. Fetal and neonatal alloimmune thrombocytopenia: harvesting the evidence to develop a clinical approach to management.
Symington A; Paes B
Am J Perinatol; 2011 Feb; 28(2):137-44. PubMed ID: 20700860
[TBL] [Abstract][Full Text] [Related]
55. True risk of fetal/neonatal alloimmune thrombocytopenia in subsequent pregnancies: a prospective observational follow-up study.
Tiller H; Husebekk A; Skogen B; Kjeldsen-Kragh J; Kjaer M
BJOG; 2016 Apr; 123(5):738-44. PubMed ID: 25752647
[TBL] [Abstract][Full Text] [Related]
56. HLA-DRB3*01:01 is a predictor of immunization against human platelet antigen-1a but not of the severity of fetal and neonatal alloimmune thrombocytopenia.
Wienzek-Lischka S; König IR; Papenkort EM; Hackstein H; Santoso S; Sachs UJ; Bein G
Transfusion; 2017 Mar; 57(3):533-540. PubMed ID: 28019029
[TBL] [Abstract][Full Text] [Related]
57. [Establishing a screening programme in Denmark for foetal and neonatal alloimmune thrombocytopenia].
Madsen C; Prahm KP; Nilsson C; Pedersen LH; Dziegiel MH; Hedegaard M
Ugeskr Laeger; 2018 Apr; 180(17):. PubMed ID: 29717700
[TBL] [Abstract][Full Text] [Related]
58. Neonatal alloimmune thrombocytopenia in Norway: poor detection rate with nonscreening versus a general screening programme.
Tiller H; Killie MK; Skogen B; Øian P; Husebekk A
BJOG; 2009 Mar; 116(4):594-8. PubMed ID: 19250370
[TBL] [Abstract][Full Text] [Related]
59. Prenatal determination of human platelet antigen type 4 by DNA amplification of amniotic fluid cells.
Ohto H; Kato K; Tohyama Y; Okubo M; Morita S; Hattori M; Takasaki K; Sugafuzi M; Imamura S; Sato A; Motoki R
Transfus Sci; 1997 Mar; 18(1):85-9. PubMed ID: 10174297
[TBL] [Abstract][Full Text] [Related]
60. Maternal HLA genotyping is not useful for predicting severity of fetal and neonatal alloimmune thrombocytopenia.
Sainio S; Javela K; Tuimala J; Haimila K
Br J Haematol; 2017 Jan; 176(1):111-117. PubMed ID: 27748520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
